BetterLife Pharma Inc. News Releases

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

Tue, 29 Sep 2026 17:59:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, today announced that its upcoming Annual General Meeting ("AGM"), originally scheduled for October 14, 2026, has been rescheduled and reclassified as an Annual General and Special Meeting ("AGSM"). The rescheduled meeting will...

BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

Thu, 17 Sep 2026 10:41:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together with the Common Shares, the...

BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

Fri, 11 Sep 2026 19:45:00 -0400

FINAL PROSPECTUS ACCESSIBLE ON SEDAR+Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British Columbia, Ontario and Alberta, in connection with the previously announced...

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Mon, 31 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee.Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly...

BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

Fri, 28 Aug 2026 08:00:00 -0400

AMENDED AND RESTATED PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has priced its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and/or pre-funded common share purchase warrants of the Company...

BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Mon, 24 Aug 2026 18:42:00 -0400

PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in...

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) application for...

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache...

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee.Mr. LaRocca is a three-decade biopharmaceutical industry executive...

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program.BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the...